Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sanofi-Aventis SA ADR News

    48,81 $ +4,72% +2,20 $
    In : 45,633 € | 15:34:40 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 662283
    ISIN: US80105N1054
    US-Symbol: SNY
    Typ: Aktie

    Sanofi-Aventis SA ADR News

    01.02.24 - wallstreet:online Zentralredaktion
    Ihre wichtigsten Termine: Alle Blicke auf: Apple, Meta, Altria, Merck, Shell und Siemens Healthineers
    Gut geplant in den Tag. Mit dem w:o-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
    23.01.24 - PR Newswire
    Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
    Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire
    02.11.23 - PR Newswire
    Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
    Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities PR Newswire
    01.11.23 - PR Newswire
    Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
    Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S. PR Newswire
    10.10.23 - PR Newswire
    Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
    Stagwell's (STGW) The Harris Poll Unveils First-​of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers PR Newswire
    13.09.23 - PR Newswire
    Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
    Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu PR Newswire
    25.07.23 - PR Newswire
    Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
    Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact PR Newswire
    20.06.23 - PR Newswire
    Thinking about trading options or stock in NVIDIA, Baidu, Lumentum Holdings, Sanofi, or AMC Entertainment?
    Thinking about trading options or stock in NVIDIA, Baidu, Lumentum Holdings, Sanofi, or AMC Entertainment? PR Newswire
    18.05.23 - PR Newswire
    Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
    Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi PR Newswire
    04.04.23 - PR Newswire
    Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
    Sanofi Breaks Ground on State-​of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines PR Newswire
    23.03.23 - PR Newswire
    Thinking about trading options or stock in Sanofi, Alibaba, Microsoft, NVIDIA, or Accenture?
    Thinking about trading options or stock in Sanofi, Alibaba, Microsoft, NVIDIA, or Accenture? PR Newswire
    18.01.23 - PR Newswire
    Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
    Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare PR Newswire
    21.12.22 - PR Newswire
    Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
    Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine PR Newswire
    15.12.22 - PR Newswire
    Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
    Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis PR Newswire
    11.11.22 - PR Newswire
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis PR Newswire
    06.10.22 - PR Newswire
    Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
    Sanofi US enters into co-​promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-​modifying therapy for type 1 diabetes PR Newswire
    28.09.22 - PR Newswire
    Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
    Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis PR Newswire
    05.09.22 - PR Newswire
    Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
    Late-​Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-​to-severe ...
    26.08.22 - PR Newswire
    Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report
    Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report PR Newswire
    12.08.22 - PR Newswire
    Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations
    Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations PR Newswire

    Newssuche

    Videos

    09:30 Uhr +49,59%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »